These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31372510)

  • 1. A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites.
    Zhang S; Sakuma M; Deora GS; Levy CW; Klausing A; Breda C; Read KD; Edlin CD; Ross BP; Wright Muelas M; Day PJ; O'Hagan S; Kell DB; Schwarcz R; Leys D; Heyes DJ; Giorgini F; Scrutton NS
    Commun Biol; 2019; 2():271. PubMed ID: 31372510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.
    Zhang S; Collier MEW; Heyes DJ; Giorgini F; Scrutton NS
    Arch Biochem Biophys; 2021 Jan; 697():108702. PubMed ID: 33275878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore-Based Virtual Screening of Novel Competitive Inhibitors of the Neurodegenerative Disease Target Kynurenine-3-Monooxygenase.
    Gotina L; Seo SH; Kim CW; Lim SM; Pae AN
    Molecules; 2021 May; 26(11):. PubMed ID: 34073016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(6-phenylpyridazin-3-yl)benzenesulfonamides as highly potent, brain-permeable, and orally active kynurenine monooxygenase inhibitors.
    Kimura H; Suda H; Kassai M; Endo M; Deai Y; Yahata M; Miyajima M; Isobe Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127753. PubMed ID: 33359168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of kynurenine 3-monooxygenase inhibition.
    Amaral M; Levy C; Heyes DJ; Lafite P; Outeiro TF; Giorgini F; Leys D; Scrutton NS
    Nature; 2013 Apr; 496(7445):382-5. PubMed ID: 23575632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors.
    Smith JR; Jamie JF; Guillemin GJ
    Drug Discov Today; 2016 Feb; 21(2):315-24. PubMed ID: 26589832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
    Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
    Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
    Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kynurenine pathway and neurodegenerative disease.
    Maddison DC; Giorgini F
    Semin Cell Dev Biol; 2015 Apr; 40():134-41. PubMed ID: 25773161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-(6-(5-fluoro-2-(piperidin-1-yl)phenyl)pyridazin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)methanesulfonamide as a brain-permeable and metabolically stable kynurenine monooxygenase inhibitor.
    Tsuboi K; Kimura H; Nakatsuji Y; Kassai M; Deai Y; Isobe Y
    Bioorg Med Chem Lett; 2021 Jul; 44():128115. PubMed ID: 34015507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.
    Phillips RS; Anderson AD; Gentry HG; Güner OF; Bowen JP
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1705-1708. PubMed ID: 28302400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase.
    Sathyasaikumar KV; Breda C; Schwarcz R; Giorgini F
    Methods Mol Biol; 2018; 1780():397-413. PubMed ID: 29856028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
    Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.
    Amaral M; Outeiro TF; Scrutton NS; Giorgini F
    J Mol Med (Berl); 2013 Jun; 91(6):705-13. PubMed ID: 23636512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kynurenine-3-monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression.
    Chen Y; Zhang J; Yang Y; Xiang K; Li H; Sun D; Chen L
    J Cell Physiol; 2022 Dec; 237(12):4339-4355. PubMed ID: 36088660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
    Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
    Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington's disease.
    Bondulich MK; Fan Y; Song Y; Giorgini F; Bates GP
    Sci Rep; 2021 Mar; 11(1):5484. PubMed ID: 33750843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.
    Giorgini F; Huang SY; Sathyasaikumar KV; Notarangelo FM; Thomas MA; Tararina M; Wu HQ; Schwarcz R; Muchowski PJ
    J Biol Chem; 2013 Dec; 288(51):36554-66. PubMed ID: 24189070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.
    Hughes TD; Güner OF; Iradukunda EC; Phillips RS; Bowen JP
    Molecules; 2022 Jan; 27(1):. PubMed ID: 35011505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.